Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tacrolimus + ruxolitinib
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Tacrolimus + ruxolitinib is an investigational combination regimen consisting of the small-molecule calcineurin inhibitor tacrolimus and the oral small-molecule Janus kinase 1 and 2 (JAK1/JAK2) inhibitor ruxolitinib. This combination is primarily evaluated as a graft-versus-host disease (GVHD) prophylaxis regimen in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT), particularly those with myelofibrosis or other hematologic malignancies. Tacrolimus acts by blocking interleukin-2 (IL-2)-mediated T-cell activation and proliferation, while ruxolitinib targets the JAK-STAT pathway to suppress inflammatory cytokine signaling. The combination is typically administered alongside other agents, such as methotrexate or post-transplant cyclophosphamide, to reduce the incidence and severity of acute and chronic GVHD.
- Other names
- Tac/RuxTac/Ruxoruxolitinib + tacrolimusruxolitinib and tacrolimusruxolitinib plus tacrolimustacrolimus and ruxolitinibtacrolimus plus ruxolitinib
02
Targets
Beyond the preview
Go deeper on tacrolimus + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tacrolimus + ruxolitinib.